Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
QuintilesIMS
UBS
Deloitte
Cantor Fitzgerald
Merck
Medtronic
Express Scripts

Generated: October 22, 2018

DrugPatentWatch Database Preview

RABEPRAZOLE SODIUM Drug Profile

« Back to Dashboard

When do Rabeprazole Sodium patents expire, and what generic alternatives are available?

Rabeprazole Sodium is a drug marketed by Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Breckenridge Pharm, Dr Reddys Labs Ltd, Lannett Co Inc, Lupin Ltd, Mylan Pharms Inc, Teva Pharms Usa, and Torrent Pharms Ltd. and is included in ten NDAs.

The generic ingredient in RABEPRAZOLE SODIUM is rabeprazole sodium. There are thirty drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

Drug patent expirations by year for RABEPRAZOLE SODIUM
Pharmacology for RABEPRAZOLE SODIUM
Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors
Medical Subject Heading (MeSH) Categories for RABEPRAZOLE SODIUM
Synonyms for RABEPRAZOLE SODIUM
(S)-Rabeprazole Sodium Salt
[2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
1017795-22-0
117976-90-6
129982-41-8
171440-19-0
1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1)
1H-Benzimidazole,2-(((4-(3-methoxypropxy)-3-methyl-2-pyridinyl)methyl)sufinyl)-,sodium salt
1H-Benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium salt
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole sodium salt
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1 H -benzimidazole sodium salt
226904-80-9
976R906
AB0013367
AC-715
AC1Q1W5D
Aciphex (TN)
Aciphex Sodium
Aciphex Sprinkle
AK-94764
AKOS015895734
AKOS015962116
AKOS025310160
AM81231
AN-15565
API0004026
AS-13338
AX8150186
BC208315
BG0517
C07865
C18H20N3NaO3S
C18H20N3O3S.Na
CAS-117976-90-6
CCG-213574
CHEBI:8769
CHEMBL1200930
CR0021
CTK8E9030
D00724
DR002161
DSSTox_CID_24205
DSSTox_GSID_44205
DSSTox_RID_80118
DTXSID3044205
E 3810
E3810
EX-A176
FT-0631090
H932
Habeprazole Sodium
HMS2093H10
HMS2231E04
HMS3373B05
J-010726
J10481
KB-301660
KRCQSTCYZUOBHN-UHFFFAOYSA-N
KS-00000H0Y
LS-172366
LY 307640 sodium
LY-307640
LY307640 sodium
MFCD02092688
MLS001165734
MLS006010621
MolPort-003-850-098
MolPort-003-986-282
natrium-2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-id
NCGC00159518-02
NCGC00159518-05
NCGC00255838-01
Pariet
Pariet (TN)
pariete
Pariprazole sodium
Pepcia
Q-201655
R0115
Rabeprazole sodium (JP17/USAN)
Rabeprazole sodium [USAN]
Rabeprazole sodium salt
Rabeprazole sodium, >=98% (HPLC)
Rabicip
Rebeprazole sodium
Rebeprazole sodium salt
Rebeprazole sodium;
RTC-063564
S-7685
s4665
SC-19471
SCHEMBL140494
SMR000550493
sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
sodium 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-ide
SODIUM RABEPRAZOLE(1-)
sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
ST24049115
ST51052899
TC-063564
TL8000495
Tox21_111736
Tox21_111736_1
Tox21_302317

US Patents and Regulatory Information for RABEPRAZOLE SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkem Labs Ltd RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 208644-001 Apr 24, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lupin Ltd RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 078964-001 Nov 8, 2013 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Breckenridge Pharm RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 204237-001 Nov 18, 2015 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Pharms Inc RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 076885-001 Nov 8, 2013 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Amneal Pharms RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 204179-001 Jul 31, 2015 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
QuintilesIMS
UBS
Deloitte
Cantor Fitzgerald
Merck
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.